GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Operating Expenses | 6,764 | 16,056 | 250,069 | 135,570 | 9,374 |
| Operating Income | -6,764 | -16,056 | -250,069 | -135,570 | -9,374 |
| Interest Expense | 3,003 | 2,128 | 9,117 | 8,602 | 6,555 |
| Other Income | -18,529 | -20,463 | 0 | 0 | 25,697 |
| Pre-tax Income | -28,296 | -38,647 | -259,186 | -144,172 | 9,768 |
| Net Income Continuous | -28,296 | -38,647 | -259,186 | -144,172 | 9,768 |
| Net Income | $-28,296 | $-38,647 | $-259,186 | $-144,172 | $9,768 |
| EPS Basic Total Ops | -193.69 | -0.30 | -2,635.29 | -4,392.15 | 61,239.81 |
| EPS Basic Continuous Ops | -193.78 | -342.96 | -2,634.76 | -4,390.89 | 61,240.63 |
| EPS Diluted Total Ops | -193.69 | -0.30 | -2,635.29 | -4,392.15 | 61,239.81 |
| EPS Diluted Continuous Ops | -193.78 | -342.96 | -2,634.76 | -4,390.89 | 61,240.63 |
| EPS Diluted Before Non-Recurring Items | -193.69 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-6,447 | $-15,547 | $-240,323 | $-130,654 | $-6,476 |